All Articles

Beyond the polish, the rise of companies like Pudu Robotics reveals the real story: an AI-driven digital infrastructure is quietly rewiring our cities.

XChange TEC's plan to acquire AI firm First Cycle reveals a bold strategy to automate insurance from the ground up, moving beyond distribution to core operations.

Korean firm Wooree Green Science enters the U.S. with LipoPrime™, betting that measurable quality and scientific proof can win in a crowded market.

New research shows soaring housing costs are pushing residents out, creating an urgent economic and social challenge that state leaders are scrambling to address.

Despite a sharp performance dip in July driven by an AI stock selloff, investors continue to pour capital into hedge funds for the seventh straight month.

AM Best's top-tier rating affirms National Life Group's market strength, but a deeper look reveals a strategy balancing aggressive growth with complex challenges.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

Lucid Diagnostics reports rising revenue and a key insurance win for its EsoGuard test, but its financial future hangs in the balance of a pivotal Medicare decision.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

XbotGo's landmark deal with Best Buy isn't just a retail win; it's a signal that AI is finally becoming the ultimate tool for the modern family.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

With a blockbuster IPO and dazzling growth, Bending Spoons looks unstoppable. But a closer look reveals a high-stakes strategy built on massive debt.

SPXChart's new platform promises to show everyday traders the market's hidden plumbing. But can it truly level the playing field against Wall Street's titans?

Kolibri Global Energy shatters records with a 109% revenue jump, but the real story lies underground with a new strategy to unlock vast, untapped reserves.

Radian has bet its future on a massive strategic pivot. New CEO Mike Weinbach brings a mortgage tech playbook to a complex global insurance game. Will it work?

A German research award for a Chinese tech firm may seem niche, but it's a critical signal. DoGo Power's technology is a direct answer to a looming crisis.

Tidewater Midstream's record Q2 results reveal a powerful strategy: leveraging renewable fuel growth to slash debt and boost guidance. A deep dive.

Data shows a sharp rise in office downsizing. It's not a retreat, but a strategic realignment for the hybrid era, creating a new, complex logistics industry.

A Hong Kong wet trades firm is buying into a European spa distributor. A bold strategic leap or a risky diversification into an unfamiliar market?

22nd Century Group's latest earnings show a company in deep transition, intentionally sacrificing revenue and burning cash to build a future on its FDA-backed low-nicotine cigarettes. Can this costly pivot create a resilient market leader?